Where Anti-GPCR autoantibodies (panel) is reported
Also listed as: 16 autoantibodies tested; Anti-GPCR autoantibodies; G-protein coupled receptor Abs; GPCR autoAbs
| Condition | Direction | Compared against | Associated symptoms | Source |
|---|---|---|---|---|
| Long COVID | ↑ elevated | healthy controls | Dysautonomia, POTS | Wilhelm et al. 2026 |
| ME/CFS | ↑ elevated | healthy controls; long COVID/post-acute COVID-19 vaccination syndrome overlap | Dysautonomia | Maksoud et al. 2023 |
| PACVS | ↑ elevated | healthy controls | Dysautonomia, vascular instability | Mantovani et al. 2024 |
Frequently asked questions
In which conditions is Anti-GPCR autoantibodies (panel) altered?
In the OSMF atlas Anti-GPCR autoantibodies (panel) is reported in Long COVID, ME/CFS, PACVS. It is elevated in 3 across 3 entries.
Does Anti-GPCR autoantibodies (panel) point to one specific diagnosis?
No. Because Anti-GPCR autoantibodies (panel) changes in several conditions (Long COVID, ME/CFS, PACVS), an abnormal result cannot identify which condition, if any, is present. It must be interpreted with symptoms, history and other tests.
Is there a standard clinical test for Anti-GPCR autoantibodies (panel)?
The atlas entries for Anti-GPCR autoantibodies (panel) do not carry a LOINC code, which usually means the marker was measured with research assays or study-specific methods rather than a routine clinical panel.
Is one abnormal Anti-GPCR autoantibodies (panel) result diagnostic?
No single biomarker result is diagnostic of any of these conditions. Findings reflect group averages from published cohorts with substantial overlap between patients and controls.
Cite this page
Subscribe on Substack
Last reviewed: 2026-06-30 · Browse: Biomarker Index · All marker pages · Biomarker Atlas
Disclaimer: Educational synthesis of peer-reviewed research; not medical advice. Findings are group-level and vary with study design. Discuss any result with a qualified clinician.